Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis

AIDS ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Rogers Sekabira ◽  
Ian Mcgowan ◽  
Krista Yuhas ◽  
Rhonda M. Brand ◽  
Mark A. Marzinke ◽  
...  
Keyword(s):  
Colorectal Tissue ◽  
Preexposure Prophylaxis

scholarly journals Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis

2019 ◽  
Vol 64 (2) ◽  
Author(s):  
Nithya Srinivas ◽  
Mackenzie Cottrell ◽  
Kaitlyn Maffuid ◽  
Heather A. Prince ◽  
Julie A. E. Nelson ◽  
...  
Keyword(s):  
Drug Exposure ◽  
Female Genital Tract ◽  
Mucosal Tissue ◽  
Colorectal Tissue ◽  
Preexposure Prophylaxis ◽  
Pharmacodynamic Analysis ◽  
Immunodeficiency Virus ◽  
Dosing Strategies ◽  
Female Genital

ABSTRACT Maraviroc-based regimens have been explored as preexposure prophylaxis (PrEP) against human immunodeficiency virus (HIV). In this study, we utilized mucosal tissue drug exposure data, combined with target concentrations generated in vitro, in a pharmacokinetic-pharmacodynamic analysis to predict the effects of drug combinations and adherence on PrEP efficacy. Mucosal tissue concentrations of maraviroc were measured in 24 healthy women. The 90% effective concentrations (EC90) of maraviroc (alone and combined with tenofovir and emtricitabine) for protection against HIV were identified in CD4+ T cells. Monte Carlo simulations were performed to identify dosing strategies to protect colorectal and female genital tract (FGT) tissues from HIV infection. Colorectal maraviroc concentrations were 350-fold higher than in the FGT. Under steady-state conditions, our model predicted that one 300-mg dose/week was sufficient to protect colorectal tissue from HIV in 99% of the population, while 300 mg daily would protect the FGT in only 63% of the population. FGT protection increased to >90% when maraviroc was used in combination with tenofovir (5 doses/week) or emtricitabine (3 doses/week). Poor adherence resulted in a drastic decrease in efficacy in the FGT but not colorectal tissue. However, greater forgiveness was seen when maraviroc was combined with tenofovir or emtricitabine, suggesting that maraviroc should not be used alone as PrEP.

Differentiation of Tumour from Normal Colorectal Tissue by SELDI-MS Protein Profiling

Endoscopy ◽  
2004 ◽  
Vol 36 (05) ◽  
Author(s):  
AM Lennon ◽  
D Stuart ◽  
AC Tan ◽  
E Fox ◽  
KS Sheahan ◽  
...  
Keyword(s):  
Protein Profiling ◽  
Colorectal Tissue ◽  
Normal Colorectal Tissue

scholarly journals Trends in Reported Sexual Behavior and Y-Chromosomal DNA Detection Among Female Sex Workers in the Senegal Preexposure Prophylaxis Demonstration Project

2020 ◽  
Vol 47 (5) ◽  
pp. 314-320 ◽  
Author(s):  
D. Allen Roberts ◽  
Stephen E. Hawes ◽  
Mame D. Bousso Bao ◽  
Anna Julienne Ndiaye ◽  
Daouda Gueye ◽  
...  
Keyword(s):  
Sexual Behavior ◽  
Sex Workers ◽  
Female Sex Workers ◽  
Dna Detection ◽  
Demonstration Project ◽  
Chromosomal Dna ◽  
Female Sex ◽  
Preexposure Prophylaxis

scholarly journals Tenofovir Alafenamide for HIV Preexposure Prophylaxis

2020 ◽  
Vol 173 (1) ◽  
pp. 78
Author(s):  
Douglas S. Krakower ◽  
Demetre C. Daskalakis ◽  
Judith Feinberg ◽  
Julia L. Marcus
Keyword(s):  
Preexposure Prophylaxis ◽  
Tenofovir Alafenamide

scholarly journals Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection

JAMA ◽  
2019 ◽  
Vol 321 (14) ◽  
pp. 1380 ◽  
Author(s):  
Michael W. Traeger ◽  
Vincent J. Cornelisse ◽  
Jason Asselin ◽  
Brian Price ◽  
Norman J. Roth ◽  
...  
Keyword(s):  
High Risk ◽  
Hiv Infection ◽  
Sexually Transmitted Infections ◽  
Sexually Transmitted ◽  
Preexposure Prophylaxis

Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis

2020 ◽  
Vol 173 (6) ◽  
pp. 507-508
Author(s):  
Rochelle P. Walensky ◽  
Tim Horn ◽  
Nicole C. McCann ◽  
Kenneth A. Freedberg ◽  
A. David Paltiel
Keyword(s):  
Tenofovir Disoproxil Fumarate ◽  
Preexposure Prophylaxis ◽  
Tenofovir Alafenamide
Sign in / Sign up

Export Citation Format

Share Document